thelondonsuede ha scritto:mi chiedo una cosa......mah sto infuso e visto come un vaccino o come un farmaco....perche se e un vaccino i tempi sono lunghi se e visto come un farmaco di solito i tempi sono molto piu veloci
Come un farmaco, ma di farmaci che agiscano sul genoma delle cellule non è che ce ne siano in circolazione milioni, quindi i tempi di messa in commercio non credo siano pervedibili con sicurezza. Tieni conto che siamo ancora alla fase I.
*******************************************
Brevi frasi da un’intervista che Mitsuyasu ha rilasciato a MedPageToday di oggi (ICAAC: HIV Gene Therapy Safe, Well Tolerated), da cui si comprende una delle direzioni in cui si dovrà muovere questa ricerca: capire quante cellule modificate sono necessarie per ottenere un effetto duraturo.
"
We don't know what level of gene modification is adequate" to produce such a robust response, except that it appears to be higher than what they're getting in most patients. (…) In the process they use, Mitsuyasu said, about a third of the modified CD4 cells are "bi-allelic," carrying two modified genes that are nearly immune to HIV in principle. Other cells have a single copy and still others are not affected by the modification.
(…)The most striking finding came from the treatment interruption, during which all patients saw an initial HIV viral load increase in the absence of HAART. On the other hand, three patients saw their viral load drop again markedly, including the one whose virus became undetectable.
The patient was one of the people whose CD4 cells already carried one copy of the mutated CCR5 gene; the gene therapy meant that the proportion of re-infused cells carrying two copies was about twice as high as in the other patients.
The researchers said that one implication of their work is that in order to have a similar effect in others, they may
need to find ways of increasing the proportion of modified cells that carry two copies of the modified CCR5 gene.
Indeed, the research probably means the number of modified cells is "more important than previously expected," commented Laurent Kaiser, MD, of the University Hospitals of Geneva, and a member of the conference's program committee.
And that highlights the technical and scientific challenges that still remain before the gene therapy can enter the clinic.